Absci Corp (ABSI)
About Absci Corp
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2024
- $4.5M
- Net income
- -$115.2M
- Total assets
- $216.3M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.3B
- Shares outstanding
- 139.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 22, 2021
Absci Corp (ABSI) Stock Price
- Reported a net loss of $115.2M in FY2024.
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Absci Corp.
Write a review
News about Absci Corp
News & sentiment via Polygon.io
Absci Corp: frequently asked questions
Is Absci Corp an American company?
Absci Corp is a US-based company headquartered in Vancouver, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Absci Corp headquartered?
Absci Corp is headquartered in Vancouver, Washington, United States.
Is Absci Corp publicly traded?
Yes — Absci Corp is a publicly traded company. Its stock trades under the ticker symbol ABSI on the NASDAQ.
What does Absci Corp do?
Absci Corp is an American Pharmaceuticals company in the Health & Beauty sector.
